But which one should you choose
Back Capozzi, ME, DiMarchi, RD, Tschp, MH, et al (13 June 2019) Targeting the incretin/glucagon system with triagonists to treat diabetes', Endocrine Reviews , 39/5, 719-38
Data Availability Statement The data presented in this study are available on request from the Corresponding Author.
Looney and his team have documented that BM-MSC cells from patients with SLE or lupus model mice are a mix of senescent and healthy cells, and that treatment with FOXO4-DRI can selectively induce apoptosis in senescent cells, allowing the healthy cells to continue to grow and multiply
This mechanism is completely distinct from growth hormones receptor-mediated actions
Viral Shah, an endocrinologist and director of diabetes clinical research at the Center for Diabetes and Metabolic Diseases at the Indiana University School of Medicine in Indianapolis